Christina M Marra1, Lauren C Tantalo2, Sharon K Sahi2, Shelia B Dunaway3, Sheila A Lukehart4. 1. Department of Neurology Department Medicine (Infectious Diseases). 2. Department of Neurology. 3. Department Medicine (Infectious Diseases). 4. Department Medicine (Infectious Diseases) Department Global Health, Harborview Medical Center, University of Washington, Seattle.
Abstract
BACKGROUND: Human immunodeficiency virus (HIV)-infected individuals may have poorer serological responses to syphilis treatment and may be more likely to experience neurosyphilis. Treponema pallidum is cleared from sites of infection by opsonization, ingestion, and killing by macrophages. METHODS: Serum samples from 235 individuals with syphilis were tested for T. pallidum-specific opsonic activity. Blood T. pallidum concentrations were determined by real-time polymerase chain reaction amplification of the tp0574 gene, and T. pallidum was detected in cerebrospinal fluid (CSF) by reverse-transcriptase polymerase chain reaction of 16S ribosomal RNA. RESULTS: Opsonic activity was higher with higher serum rapid plasma reagin titers (P < .001), and in those treated for uncomplicated syphilis before serum collection (P < .001). Opsonic activity was lower in HIV-infected than in HIV-uninfected individuals even after the above factors were taken into account (P = .006). In participants in whom blood T. pallidum was detectable, those with the highest opsonic activity had lower blood T. pallidum concentrations. In multivariable analyses, there was not a significant relationship between opsonic activity and detection of T. pallidum in CSF or CSF-VDRL reactivity. CONCLUSIONS: Serum T. pallidum-specific opsonic activity is significantly lower in HIV-infected individuals. Impaired T. pallidum-specific immune responses could contribute to differences in the course of disease or treatment response.
BACKGROUND: Human immunodeficiency virus (HIV)-infected individuals may have poorer serological responses to syphilis treatment and may be more likely to experience neurosyphilis. Treponema pallidum is cleared from sites of infection by opsonization, ingestion, and killing by macrophages. METHODS: Serum samples from 235 individuals with syphilis were tested for T. pallidum-specific opsonic activity. Blood T. pallidum concentrations were determined by real-time polymerase chain reaction amplification of the tp0574 gene, and T. pallidum was detected in cerebrospinal fluid (CSF) by reverse-transcriptase polymerase chain reaction of 16S ribosomal RNA. RESULTS: Opsonic activity was higher with higher serum rapid plasma reagin titers (P < .001), and in those treated for uncomplicated syphilis before serum collection (P < .001). Opsonic activity was lower in HIV-infected than in HIV-uninfected individuals even after the above factors were taken into account (P = .006). In participants in whom blood T. pallidum was detectable, those with the highest opsonic activity had lower blood T. pallidum concentrations. In multivariable analyses, there was not a significant relationship between opsonic activity and detection of T. pallidum in CSF or CSF-VDRL reactivity. CONCLUSIONS: Serum T. pallidum-specific opsonic activity is significantly lower in HIV-infected individuals. Impaired T. pallidum-specific immune responses could contribute to differences in the course of disease or treatment response.
Authors: Meagan W Moore; Adriana R Cruz; Carson J LaVake; Amanda L Marzo; Christian H Eggers; Juan C Salazar; Justin D Radolf Journal: Infect Immun Date: 2007-01-12 Impact factor: 3.441
Authors: Agnès Libois; Stéphane De Wit; Bénédicte Poll; Felipe Garcia; Eric Florence; Ana Del Rio; Paquita Sanchez; Eugenia Negredo; Marc Vandenbruaene; José M Gatell; Nathan Clumeck Journal: Sex Transm Dis Date: 2007-03 Impact factor: 2.830
Authors: Roger Eagan; Homer L Twigg; Neil French; Janelisa Musaya; Richard B Day; Eduard E Zijlstra; Helen Tolmie; David Wyler; Malcolm E Molyneux; Stephen B Gordon Journal: Clin Infect Dis Date: 2007-05-10 Impact factor: 9.079
Authors: Christina M Marra; Clare L Maxwell; Stacy L Smith; Sheila A Lukehart; Anne M Rompalo; Molly Eaton; Bradley P Stoner; Michael Augenbraun; David E Barker; James J Corbett; Mark Zajackowski; Charles Raines; Judith Nerad; Romina Kee; Scott H Barnett Journal: J Infect Dis Date: 2004-01-27 Impact factor: 5.226
Authors: A Centurion-Lara; C Castro; L Barrett; C Cameron; M Mostowfi; W C Van Voorhis; S A Lukehart Journal: J Exp Med Date: 1999-02-15 Impact factor: 14.307
Authors: Christina M Marra; Clare L Maxwell; Sharon K Sahi; Lauren C Tantalo; Shelia B Dunaway; Sheila A Lukehart Journal: Clin Infect Dis Date: 2020-08-22 Impact factor: 9.079
Authors: Christina M Marra; Clare L Maxwell; Sharon K Sahi; Lauren C Tantalo; Shelia B Dunaway; Sheila A Lukehart Journal: Clin Infect Dis Date: 2022-03-01 Impact factor: 9.079
Authors: Sascha Knauf; Jane Raphael; Oriol Mitjà; Inyasi A V Lejora; Idrissa S Chuma; Emmanuel K Batamuzi; Julius D Keyyu; Robert Fyumagwa; Simone Lüert; Charmie Godornes; Hsi Liu; Christiane Schwarz; David Šmajs; Philippe Grange; Dietmar Zinner; Christian Roos; Sheila A Lukehart Journal: EBioMedicine Date: 2016-07-28 Impact factor: 8.143
Authors: Michael L Rekart; Wilfred Ndifon; Robert C Brunham; Jonathan Dushoff; Sang Woo Park; Sanjana Rawat; Caroline E Cameron Journal: Sex Transm Infect Date: 2017-01-16 Impact factor: 3.519
Authors: Kelly L Hawley; Adriana R Cruz; Sarah J Benjamin; Carson J La Vake; Jorge L Cervantes; Morgan LeDoyt; Lady G Ramirez; Daniza Mandich; Mary Fiel-Gan; Melissa J Caimano; Justin D Radolf; Juan C Salazar Journal: Front Immunol Date: 2017-10-05 Impact factor: 7.561
Authors: Raynell Lang; Ron Read; Hartmut B Krentz; Mingkai Peng; Soheil Ramazani; Quang Vu; M John Gill Journal: BMJ Open Date: 2018-07-10 Impact factor: 2.692